Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification

Ingrid J. Guldvik, Verena Zuber, Peder R. Braadland, Helene H. Grytli, Håkon Ramberg, Wolfgang Lilleby, Bernd Thiede, Manuela Zucknick, Fahri Saatcioglu, Randi Gislefoss, Rune Kvåle, Anne George, Henrik Grönberg, Fredrik Wiklund, David E. Neal, Vincent J. Gnanapragasam, Kristin A. Taskén, Ian G. Mills

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

High blood levels of leucine-rich α-2-glycoprotein 1 (LRG1) is unfavourable in patients with newly diagnosed high-risk or metastatic prostate cancer. Implementation of a blood test for LRG1 alongside standard risk stratification schemes could provide higher precision in treatment decisions.

Original languageEnglish
Pages (from-to)51-60
Number of pages10
JournalEuropean Urology Open Science
Volume21
DOIs
StatePublished - Oct 2020
Externally publishedYes

Keywords

  • Biomarker
  • Leucine-rich α-2-glycoprotein 1
  • Noninvasive
  • Prostate cancer

Fingerprint

Dive into the research topics of 'Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification'. Together they form a unique fingerprint.

Cite this